Lipocine Inc.
LPCN$54M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSALT LAKE CITY
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Apr 15, 2026
18dMarket Overview
Stock performance and key metrics
LPCN News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
LPCN 1154A
Depression, Postpartum
Oral testosterone undecanoate, LPCN 1021
Male Hypogonadism
LPCN 1021
Hypogonadism, Male
LPCN 1144 Formulation A
Nonalcoholic Steatohepatitis (NASH)
LPCN 1144
NASH - Nonalcoholic Steatohepatitis
LPCN 1148
Liver Cirrhosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LPCN 1154A | Phase 3 | Depression, Postpartum | - | - |
Oral testosterone undecanoate, LPCN 1021 | Phase 3 | Male Hypogonadism | - | - |
LPCN 1021 | Phase 3 | Hypogonadism, Male | - | - |
LPCN 1144 Formulation A | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
LPCN 1144 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
LPCN 1148 | Phase 2 | Liver Cirrhosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply